Treatment of IgM antibody associated polyneuropathies using rituximab

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 4, 2003, Pages 485-489

  Pestronk, A ^a   Florence, J ^a   Miller, T ^b   Choksi, R ^a   Al Lozi, M T ^a   Levine, T D ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Good Samaritan Rehab Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD20 ANTIGEN; CELL SURFACE MARKER; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; RITUXIMAB;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CHILL; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DYNAMOMETRY; HUMAN; HYPOTENSION; MUSCLE STRENGTH; NEUROMUSCULAR DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS; MUSCULOSKELETAL PHYSIOLOGY; OUTCOME ASSESSMENT (HEALTH CARE); POLYNEUROPATHIES; TIME FACTORS;

EID: 0037382265     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.4.485     Document Type: Article

References (25)

1. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62.
2. Leger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controrled study. Brain 2001;124:145-53.
3. Nobile-Orazio E, Cappellari A, Meucci N, et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 2002;72:761-6.
4. Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology 1998;51:S22-4.
5. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001;115:4-18.
6. Elliott JL, Pestronk A. Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin. Neurology 1994;44:967-8.
7. Van Den Berg-Vos RM, Franssen H, Wokke JH, et al. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125:1875-86.
8. Feldman EL, Bromberg MB, Albers JW, et al. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991;30:397-401.
9. Pestronk A, Lopate G, Kornberg AJ, et al. Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology 1994;44:2027-31.
10. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology 1995;45:1577-80.
11. Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710-17.
12. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: treatment with B-cell depletion chemotherapy using rituximab. Neurology 1999;52:1701-4.
13. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer 2001;85:1619-23.
14. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
15. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia. J Immunother 2001;24:272-9.
16. Pestronk A. St Louis, MO: Neuromuscular Disease Center, Washington University School of Medicine, 2002. (http://www.neuro.wustl.edu/neuromuscular/antibody/pnimdem.html)
17. Ortiz N, Rosa R, Gallardo E, et al. IgM monoclonal antibody against terminal moiety of GM2, GaINAc-GD1a and GaINAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release. J Neuroimmunol 2001;119:114-23.
18. Erb S, Ferracin F, Fuhr P, et al. Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies. J Neurol 2000;247:767-72.
19. Beck M, Giess R, Wurffel W, et al. Comparison of maximal voluntary isometric contraction and Drachman's hand-held dynamometry in evaluating patients with amyotrophic lateral sclerosis. Muscle Nerve 1999;22:1265-70.
20. Pestronk A, Li F, Bieser K, et al. Anti-MAG antibodies: major effects of antigen purity and antibody cross-reactivity on ELISA results and clinical correlation. Neurology 1994;44:1131-7.
21. Pestronk A, Choksi R. Multifocal motor neuropathy: serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology 1997;49:1289-92.
22. Lopate G, Choksi R, Pestronk A. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle Nerve 2002;25:828-36.
23. Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 2000;22:295-301.
24. Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-3.
25. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-7.